Plasma miR-208 as a Biomarker of Myocardial Injury

Ji, Xu; Takahashi, Rie; Hiura, Yumiko; Hirokawa, Go; Fukushima, Yasue; Iwai, Naoharu

doi:10.1373/clinchem.2009.125310

Cited by 439 publications

(326 citation statements)

References 33 publications

Supporting

Mentioning

302

Contrasting

Unclassified

Order By: Relevance

“…Increases in circulating miRNAs upon cell damage have been detected by RT-PCR-based approaches for liver, brain, and skeletal muscle (5), as well as heart (19,46 instances miRNAs even performed better than established protein biomarkers (5). Our analysis indicated that heart-specific myomirs performed similar to the highly sensitive cTnI assay, but we were unable to verify the utility of any recently proposed miRNA biomarker for HF (18,(20)(21)(22).…”

Section: Discussionmentioning

confidence: 99%

Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers

Akat

Moore-McGriff

Morozov

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

217

210

View full text Add to dashboard Cite

Heart failure (HF) is associated with high morbidity and mortality and its incidence is increasing worldwide. MicroRNAs (miRNAs) are potential markers and targets for diagnostic and therapeutic applications, respectively. We determined myocardial and circulating miRNA abundance and its changes in patients with stable and end-stage HF before and at different time points after mechanical unloading by a left ventricular assist device (LVAD) by small RNA sequencing. miRNA changes in failing heart tissues partially resembled that of fetal myocardium. Consistent with prototypical miRNAtarget-mRNA interactions, target mRNA levels were negatively correlated with changes in abundance for highly expressed miRNAs in HF and fetal hearts. The circulating small RNA profile was dominated by miRNAs, and fragments of tRNAs and small cytoplasmic RNAs. Heart-and muscle-specific circulating miRNAs (myomirs) increased up to 140-fold in advanced HF, which coincided with a similar increase in cardiac troponin I (cTnI) protein, the established marker for heart injury. These extracellular changes nearly completely reversed 3 mo following initiation of LVAD support. In stable HF, circulating miRNAs showed less than fivefold differences compared with normal, and myomir and cTnI levels were only captured near the detection limit. These findings provide the underpinning for miRNA-based therapies and emphasize the usefulness of circulating miRNAs as biomarkers for heart injury performing similar to established diagnostic protein biomarkers.exRNA | body fluids | miRNA-mRNA regulation | development | cardiovascular disease

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers

Akat

Moore-McGriff

Morozov

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

217

210

View full text Add to dashboard Cite

show abstract

“…Four cardiac miRNAs (miR-208a, miR-499, miR-1, and miR-133) are found to be consistently elevated in plasma of AMI patients within hours after the onset of infarction. (130)(131)(132)(133)(134)(135)(136)(137)(138) Of these 4 miRNAs, miR-208a, which is encoded by an intron of the aMHC gene, is to the best of our knowledge the only heart-specific miRNA. (139) The other 3 miRNAs (miR-499, miR-1, and miR-133), besides being highly expressed in the heart, are also expressed in skeletal muscle.…”

Section: Mirnas In Glucose Homeostasismentioning

confidence: 99%

MicroRNAs in Cardiometabolic Diseases

Meiliana

Wijaya

2013

Indones Biomed J

View full text Add to dashboard Cite

BACKGROUND: MicroRNAs (miRNAs) are ~22-nucleotide noncoding RNAs with critical functions in multiple physiological and pathological processes. An explosion of reports on the discovery and characterization of different miRNA species and their involvement in almost every aspect of cardiac biology and diseases has established an exciting new dimension in gene regulation networks for cardiac development and pathogenesis.CONTENT: Alterations in the metabolic control of lipid and glucose homeostasis predispose an individual to develop cardiometabolic diseases, such as type 2 diabetes mellitus and atherosclerosis. Work over the last years has suggested that miRNAs play an important role in regulating these physiological processes. Besides a cell-specific transcription factor profile, cell-specific miRNA-regulated gene expression is integral to cell fate and activation decisions. Thus, the cell types involved in atherosclerosis, vascular disease, and its myocardial sequelae may be differentially regulated by distinct miRNAs, thereby controlling highly complex processes, for example, smooth muscle cell phenotype and inflammatory responses of endothelial cells or macrophages. The recent advancements in using miRNAs as circulating biomarkers or therapeutic modalities, will hopefully be able to provide a strong basis for future research to further expand our insights into miRNA function in cardiovascular biology. ISI:Perubahan kendali metabolisme lemak dan homeostasis glukosa pada individu dapat memicu berkembangnya penyakit kardiometabolik seperti diabetes melitus tipe 2 dan aterosklerosis. Penelitian yang dilakukan pada dasawarsa terakhir telah menunjukkan bahwa miRNA memiliki peran penting dalam pengaturan proses fisiologi ini. Selain profil faktor transkripsi spesifik sel, ekspresi gen yang diregulasi oleh miRNA mempengaruhi tujuan akhir perkembangan dan keputusan aktivasi sel. Jadi, tipe sel yang terlibat dalam aterosklerosis, penyakit vaskular, dan kerusakan miokardial mungkin diregulasi secara berbeda oleh miRNA yang berlainan, melalui proses pengaturan yang sangat rumit, misalnya fenotipe sel otot polos dan respon inflamasi sel endotel atau makrofag. Perkembangan terakhir dalam hal penggunaan miRNA sebagai biomarker atau modalitas terapi diharapkan dapat menjadi dasar yang kuat untuk penelitian lebih lanjut, sehingga dapat memperkaya pemahaman kita mengenai fungsi miRNA pada biologi kardiovaskular. RINGKASAN:MiRNA adalah noncoding RNA yang kecil, berfungsi sebagai pengatur post-transkripsi pada ekspresi gen. MiRNA merupakan modulator potensial pada berbagai proses dan patologi biologi. Penemuan yang ada menunjukkan pentingnya peran miRNA pada vaskulatur, alur metabolisme lemak, dan homeostasis glukosa. Abstract Abstrak R E V I E W A R T I C L E

show abstract

“…However, recent studies have shown that in long events such as heart injuries, this miRNA can flow into the bloodstream and be detected in peripheral blood. Thus, its levels of expression may be linked to the diagnosis and prognosis of diseases 17,18 .…”

Section: Micrornas and The Cardiovascular Systemmentioning

confidence: 99%

“…The first study in mice showed that the plasma level of miR-208 (heart-specific miRNA) is related to myocardial injury and is detectable after induction of this injury 18 . In humans, the miRNAs miR-1 32,33 , miR-133 34 , miR-208a 35 and miR-499 36 have been proposed as good biomarkers of acute myocardial infarction, showing significantly higher plasma levels compared to patients without this condition.…”

Section: Micrornas In Cardiac Hypertrophy and Heart Failurementioning

confidence: 99%

MicroRNAs: um novo paradigma no tratamento e diagnóstico da insuficiência cardíaca?

Oliveira-Carvalho¹,

Carvalho²,

Silva³

et al. 2012

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a group of newly discovered small RNAs, non-coding, which represent one of the most exciting areas of modern medical science as they modulate a huge and complex regulatory network of gene expression. Lines of evidence have recently suggested that miRNAs play a key role in the pathogenesis of heart failure. Some miRNAs highly expressed in the heart, such as miR-1, miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains controversial. Serum levels of circulating miRNAs such as miR-423-5p are being evaluated as potential biomarkers in the diagnosis and prognosis of heart failure. On the other hand, the manipulation of levels of miRNAs using techniques such as mimicking the miRNAs (miRmimics) and antagonistic miRNAs (antagomiRs) is making increasingly evident the enormous potential of miRNAs as promising therapeutic strategies in heart failure.

show abstract

Plasma miR-208 as a Biomarker of Myocardial Injury

Cited by 439 publications

References 33 publications

Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers

Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers

MicroRNAs in Cardiometabolic Diseases

MicroRNAs: um novo paradigma no tratamento e diagnóstico da insuficiência cardíaca?

Contact Info

Product

Resources

About